ES2182131T3 - Vacuna de pertussis acelular con toxoides de difteria y tetanos. - Google Patents

Vacuna de pertussis acelular con toxoides de difteria y tetanos.

Info

Publication number
ES2182131T3
ES2182131T3 ES97950137T ES97950137T ES2182131T3 ES 2182131 T3 ES2182131 T3 ES 2182131T3 ES 97950137 T ES97950137 T ES 97950137T ES 97950137 T ES97950137 T ES 97950137T ES 2182131 T3 ES2182131 T3 ES 2182131T3
Authority
ES
Spain
Prior art keywords
difteria
tetans
accelular
toxoids
pertussis vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97950137T
Other languages
English (en)
Inventor
Patrick Florent
Jean Stephenne
Christian Vandecasserie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Application granted granted Critical
Publication of ES2182131T3 publication Critical patent/ES2182131T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SUMINISTRA UNA VACUNA PARA LA DIFTERIA, EL TETANOS Y LA TOS FERINA QUE COMPRENDE UNA DOSIS BAJA DE TOXOIDE DE LA DIFTERIA (D), TOXOIDE DEL TETANOS (T), TOXINA DE LA TOS FERINA (PT), HEMAGLUTINA FILAMENTOSA (FHA) Y PERTACTINA (69K). LA VACUNA MANTIENE LA CAPACIDAD DE EVITAR LA TOS FERINA MIENTRAS QUE MUESTRA UNA REACTOGENICIDAD EXCEPCIONALMENTE BAJA. TAMBIEN SE SUMINISTRAN VACUNAS COMBINACIONALES QUE COMPRENDE ANTIGENOS ADICIONALES.
ES97950137T 1996-11-07 1997-11-04 Vacuna de pertussis acelular con toxoides de difteria y tetanos. Expired - Lifetime ES2182131T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition

Publications (1)

Publication Number Publication Date
ES2182131T3 true ES2182131T3 (es) 2003-03-01

Family

ID=10802615

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97950137T Expired - Lifetime ES2182131T3 (es) 1996-11-07 1997-11-04 Vacuna de pertussis acelular con toxoides de difteria y tetanos.
ES02075821T Active ES2240647T7 (es) 1996-11-07 1997-11-04 Vacuna de pertussis acelular con toxoides de difteria y tetanos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02075821T Active ES2240647T7 (es) 1996-11-07 1997-11-04 Vacuna de pertussis acelular con toxoides de difteria y tetanos.

Country Status (30)

Country Link
EP (2) EP0941117B1 (es)
JP (1) JP3980652B2 (es)
KR (1) KR100518044B1 (es)
CN (1) CN1130226C (es)
AR (1) AR011509A1 (es)
AT (2) ATE222773T1 (es)
AU (1) AU710475B2 (es)
BR (2) BR9712917A (es)
CA (1) CA2271008C (es)
CO (1) CO4910171A1 (es)
CY (2) CY2407B1 (es)
CZ (1) CZ295954B6 (es)
DE (3) DE69715031T2 (es)
DK (2) DK1240905T5 (es)
ES (2) ES2182131T3 (es)
GB (1) GB9623233D0 (es)
HK (1) HK1050473B (es)
HU (1) HU224126B1 (es)
IL (1) IL129530A (es)
LU (1) LU91183I2 (es)
NO (2) NO320186B1 (es)
NZ (1) NZ335384A (es)
PL (1) PL188460B1 (es)
PT (2) PT1240905E (es)
SA (1) SA98181128B1 (es)
SI (2) SI1240905T1 (es)
TR (1) TR199900979T2 (es)
TW (1) TW471971B (es)
WO (1) WO1998019702A1 (es)
ZA (1) ZA979984B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP5007425B2 (ja) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 百日咳ワクチンの安全性評価方法
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
CN105007936B (zh) 2013-03-08 2018-10-02 扬森疫苗与预防公司 无细胞百日咳疫苗
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
EP0278940A3 (en) 1987-01-30 1988-12-07 Smithkline Biologicals S.A. Hepatitis b virus surface antigens and hybrid antigens containing them
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
EP0414374B1 (en) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten

Also Published As

Publication number Publication date
EP1240905B3 (en) 2009-08-26
SA98181128B1 (ar) 2006-03-25
ES2240647T7 (es) 2010-03-31
IL129530A (en) 2005-11-20
BR9712917A (pt) 1999-12-07
ZA979984B (en) 1998-07-23
NO992156D0 (no) 1999-05-04
CN1236321A (zh) 1999-11-24
NO2006005I2 (no) 2010-04-12
TW471971B (en) 2002-01-11
NO2006005I1 (no) 2006-05-08
NO320186B1 (no) 2005-11-07
EP0941117A1 (en) 1999-09-15
CY2407B1 (en) 2004-09-10
ATE222773T1 (de) 2002-09-15
DE122005000046I1 (de) 2005-12-29
CZ295954B6 (cs) 2005-12-14
HK1050473A1 (en) 2003-06-27
DE69715031T2 (de) 2003-05-08
HUP9904287A1 (hu) 2000-04-28
GB9623233D0 (en) 1997-01-08
IL129530A0 (en) 2000-02-29
BRPI9712917B1 (pt) 2019-12-03
HK1022638A1 (en) 2000-08-18
KR100518044B1 (ko) 2005-09-30
WO1998019702A1 (en) 1998-05-14
PT941117E (pt) 2002-12-31
PL333127A1 (en) 1999-11-22
CA2271008A1 (en) 1998-05-14
DE69733285T3 (de) 2010-03-25
AU5319698A (en) 1998-05-29
AU710475B2 (en) 1999-09-23
DE69733285D1 (de) 2005-06-16
PT1240905E (pt) 2005-09-30
PL188460B1 (pl) 2005-02-28
ATE295178T1 (de) 2005-05-15
CO4910171A1 (es) 2000-04-24
HUP9904287A3 (en) 2001-05-28
CZ164099A3 (cs) 1999-10-13
ES2240647T3 (es) 2005-10-16
CN1130226C (zh) 2003-12-10
NZ335384A (en) 2000-10-27
EP1240905A1 (en) 2002-09-18
LU91183I2 (fr) 2005-09-20
DK1240905T3 (da) 2005-07-18
DK1240905T5 (da) 2010-01-11
JP3980652B2 (ja) 2007-09-26
SI0941117T1 (en) 2002-12-31
KR20000053092A (ko) 2000-08-25
CA2271008C (en) 2008-07-22
JP2001503422A (ja) 2001-03-13
EP1240905B1 (en) 2005-05-11
DE69733285T2 (de) 2006-01-12
HK1050473B (en) 2006-03-03
SI1240905T1 (en) 2005-10-31
HU224126B1 (hu) 2005-05-30
TR199900979T2 (xx) 1999-07-21
BRPI9712917B8 (pt) 2021-05-25
NO992156L (no) 1999-05-04
DK0941117T3 (da) 2002-11-18
AR011509A1 (es) 2000-08-30
EP0941117B1 (en) 2002-08-28
CY2568B1 (en) 2008-07-02
DE69715031D1 (de) 2002-10-02

Similar Documents

Publication Publication Date Title
AR011509A1 (es) Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
AR025750A1 (es) Vacunas
AU5741001A (en) Epitope synchronization in antigen presenting cells
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
AR020836A1 (es) Vacunas
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
AR044985A1 (es) Metodo y parche de inmunizacion por disposicion de microproyeccion
HUP9901901A2 (hu) Hepatitis C elleni vakcinák
NO20015073D0 (no) Vaksiner
FR2781159B1 (fr) Vaccin circovirus et parvovirus porcin
FI913820A0 (fi) Traodlikt hemagglutinin fraon bordetella pertussis som baerarmolekyl foer konjugatvaccin.
LU91594I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de virus poliomyélitique inactivé type 1, type 2 et type 3 (Infanrix - IPV)
MX9709870A (es) Uso de esporocistos u occistos para preparar una vacuna contra coccidiosis.
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
CY1110327T1 (el) DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ
ES2079358T3 (es) Vacuna reasociante de rotavirus.
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
GB0031079D0 (en) Vaccine
ES2104490B1 (es) Conjunto de vacunacion contra la enterotoxemia del conejo y vacuna acondicionada para ser utilizada en este conjunto.
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
ECSP961731A (es) Vacunas
CY1117601T1 (el) Ανασυνδυασμενα εμβολια κατα κωπηποδων καλιγιδων (θαλασσιων ψειρων) και αλληλουχιες αντιγονων αυτων